Dr. Reddy's Laboratories Ltd.

BSE

Price on BSE 22 Jan,13:43 LIVE

1,219.60

+64.10

(+5.55%)

Volume :
539,261.00

Prev Close :
1,155.50

Day's H/L (Rs.) :
1,225.00 - 1,188.95

52wk H/L (Rs.) :
1,377.95 - 1,025.90

Mkt Cap (Rs. Cr) :
101,787.82

NSE

Price on NSE 22 Jan,14:39 LIVE

1,218.90

+61.70

(+5.33%)

Volume :
5,169,138.00

Prev Close :
1,157.20

Day's H/L (Rs.) :
1,225.00 - 1,187.70

52wk H/L (Rs.) :
1,379.70 - 1,020.00

Mkt Cap (Rs. Cr) :
0.00

Market News

Dr Reddy's profit down 14% on low Lenalidomide US sales
Rediff.com 1 hour(s) ago

Domestic sales a booster dose for pharma revenues
Rediff.com 3 day(s) ago

Dr Reddy's Laboratories loses Rs 2.16 cr in cyber fraud
Rediff.com 10 Nov 2025

'India Should Move Quickly As Conditions Change'
Rediff.com 02 Jan 2026

Weightloss Drugs Hit 1,000 Crore Mark
Rediff.com 22 Dec 2025

Report Card - Dr. Reddy's Laboratories Ltd.

PE Ratios

18.01

EPS (Rs.)

64.14

Sales (Rs. Cr)

4,618.60

Face Value (Rs.)

Net Profit Margin(%)

23.14

Last Bonus

1:1

Last Dividend(%)

800

Return on Average Equity

18.53

News for Dr. Reddy's Laboratories Ltd.

Dr Reddy''s Q3 Profit Dips 14% to Rs 1,210 Cr

Dr Reddy''s Q3FY26 profit declines 14% to Rs 1,210 crore due to lower US sales. Revenue rises to Rs 8,727 crore. India sales up 19%.

Jan 21, 2026 18:20

Dr Reddy''s & Immutep Ink Cancer Drug Licensing Pact

Dr Reddy''s and Immutep collaborate to develop and commercialize Eftilagimod Alfa (Efti), a cancer medication, outside key markets.

Dec 08, 2025 14:49

Dr Reddy''s Biosimilar Approved in Europe

Dr Reddy''s gets EU nod for AVT03, a biosimilar of Prolia (denosumab) and Xgeva, used to treat osteoporosis and prevent bone complications.

Nov 24, 2025 17:22

Dr Reddy''s Srikakulam Unit Gets USFDA VAI

Dr Reddy''s Srikakulam facility gets Voluntary Action Indicated (VAI) status from USFDA after inspection. Inspection officially closed.

Oct 21, 2025 12:46

Glenmark, Dr Reddy''s Recall Products in US: USFDA

Glenmark and Dr Reddy''s recall products in the US due to manufacturing issues, says USFDA. Recalls include oral contraceptives and muscle relaxants.

Oct 19, 2025 10:20

More News for Dr. Reddy's Laboratories Ltd. »

News for Pharmaceuticals and health care

India Top Passenger Market for Singapore Changi Airport

India is a top passenger market for Singapore's Changi Airport. Airport added Vijayawada as new destination. Read more.

Jan 22, 2026 14:30

Indian Bank Q3 Profit Up 7% to Rs 3,061 Cr

Indian Bank reports a 7.33% rise in net profit to Rs 3,061 crore for Q3 December 2025. Gross NPAs improve. Total deposits increase by 12.62%.

Jan 22, 2026 14:30

Razorpay POS Gets RBI Nod for Offline Payments

Razorpay POS secures RBI license for offline payment aggregator. Expands in-store payment infrastructure for diverse sectors & SMEs.

Jan 22, 2026 14:23

Department of Posts Targets 30% Revenue Growth by FY26

Department of Posts aims for 30% revenue growth to Rs 17,546 crore in FY26. Scindia announces ambitious target after quarterly review.

Jan 22, 2026 14:11

AP Pitches Clean Energy at WEF 2026

Nara Lokesh promotes Andhra Pradesh as a hub for clean energy, green fuels & manufacturing at WEF 2026. Investment opportunities.

Jan 22, 2026 14:08

More News »

Top News

India Top Passenger Market for Singapore Changi Airport

India is a top passenger market for Singapore's Changi Airport. Airport added Vijayawada as new destination. Read more.

Jan 22, 2026 14:30

Indian Bank Q3 Profit Up 7% to Rs 3,061 Cr

Indian Bank reports a 7.33% rise in net profit to Rs 3,061 crore for Q3 December 2025. Gross NPAs improve. Total deposits increase by 12.62%.

Jan 22, 2026 14:30

Zee Ent Q3 Profit Declines 5% to Rs 155 Cr

Zee Entertainment Enterprises Ltd reports a 5.37% dip in Q3 net profit to Rs 154.8 crore. Ad revenue down, subscription revenue up. Stock rises.

Jan 22, 2026 14:24

Razorpay POS Gets RBI Nod for Offline Payments

Razorpay POS secures RBI license for offline payment aggregator. Expands in-store payment infrastructure for diverse sectors & SMEs.

Jan 22, 2026 14:23

Department of Posts Targets 30% Revenue Growth by FY26

Department of Posts aims for 30% revenue growth to Rs 17,546 crore in FY26. Scindia announces ambitious target after quarterly review.

Jan 22, 2026 14:11

More Top News »

Sectoral Indices Market Indicators Listed Companies Gainers Losers Mutual Funds Portfolio Watchlist